gms | German Medical Science

21. Jahrestagung der Retinologischen Gesellschaft gemeinsam mit dem
8. Symposium der International Society of Ocular Trauma

Deutsche Gesellschaft für Retinologie
International Society of Ocular Trauma

19.06. - 22.06.2008, Würzburg

Efficicy and Safety of Intravitreal Bevacizumab (Avastin) on demand in neovascular Age-related Macular Degeneration. 12 Months Results.

Meeting Abstract

Suche in Medline nach

  • Bert Müller - Berlin/Germany
  • A.U. Porstmann - Berlin/Germany

Retinologische Gesellschaft. International Society of Ocular Trauma. 21. Jahrestagung der Retinologischen Gesellschaft gemeinsam mit dem 8. Symposium der International Society of Ocular Trauma. Würzburg, 19.-22.06.2008. Düsseldorf: German Medical Science GMS Publishing House; 2008. DocISOTRG2008V111

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/rg2008/08rg112.shtml

Veröffentlicht: 18. Juni 2008

© 2008 Müller et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielf&aauml;ltigt, verbreitet und &oauml;ffentlich zug&aauml;nglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Background: Intravitreal Bevacizumab has been used off label for years in neovascular age related macular degeneration without approval from prospective studies.

Methods: prospective, open label, non randomized, investigator initiated single center trail. 26 patients (28 eyes) were enrolled to receive 2 intravitreal bevacizumab (1mg) injections within 12 weeks and were thereafter prospectively followed every 3 weeks for 12 months. Retreatment was allowed when either loss of vision of at least one line/ 5 letters occurred and/ or an active choroidal neovascularisation was detected in OCT or fluorescein angiography.

Results: After 12 months vision improved by 10.3 ETDRS letters (p=0.000) from baseline 0.25 (dec.) or 55 letters. Central macular thickness decreased by 83µm (p=0.1).These results were obtained with an average amount of 4.6 injections. Vision improved of more than 3 lines/15 letters in a third of the treated eyes, whereas 2 patients (2 eyes) experienced a severe loss of vision of more than 3 lines. Adverse ocular side effects were not observed. One patient suffered from transient ischemic cerebral attack with complete recovery.

Conclusion: This study demonstrates similiar results of intravitreal Bevacizumab on demand in neovascular ARMD with regard to the other anti-VEGF agents justfiying the need for further direct comparing clinical trails.